Literature DB >> 22543461

Ivacaftor.

Pamela B Davis, Uma Yasothan, Peter Kirkpatrick.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22543461     DOI： 10.1038/nrd3723

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  6 in total

1.  Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis.

Authors:  Isabelle Sermet-Gaudelus; Kris De Boeck; Georges J Casimir; François Vermeulen; Teresinha Leal; Agnès Mogenet; Delphine Roussel; Janine Fritsch; Laurence Hanssens; Samit Hirawat; Nilsen L Miller; Scott Constantine; Allen Reha; Temitayo Ajayi; Gary L Elfring; Langdon L Miller
Journal:  Am J Respir Crit Care Med       Date:  2010-07-09       Impact factor: 21.405

2.  Ivacaftor potentiation of multiple CFTR channels with gating mutations.

Authors:  Haihui Yu; Bill Burton; Chien-Jung Huang; Jennings Worley; Dong Cao; James P Johnson; Art Urrutia; John Joubran; Sheila Seepersaud; Katherine Sussky; Beth J Hoffman; Fredrick Van Goor
Journal:  J Cyst Fibros       Date:  2012-01-30       Impact factor: 5.482

3.  Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation.

Authors:  J P Clancy; Steven M Rowe; Frank J Accurso; Moira L Aitken; Raouf S Amin; Melissa A Ashlock; Manfred Ballmann; Michael P Boyle; Inez Bronsveld; Preston W Campbell; Kris De Boeck; Scott H Donaldson; Henry L Dorkin; Jordan M Dunitz; Peter R Durie; Manu Jain; Anissa Leonard; Karen S McCoy; Richard B Moss; Joseph M Pilewski; Daniel B Rosenbluth; Ronald C Rubenstein; Michael S Schechter; Martyn Botfield; Claudia L Ordoñez; George T Spencer-Green; Laurent Vernillet; Steve Wisseh; Karl Yen; Michael W Konstan
Journal:  Thorax       Date:  2011-08-08       Impact factor: 9.139

4.  A CFTR potentiator in patients with cystic fibrosis and the G551D mutation.

Authors:  Bonnie W Ramsey; Jane Davies; N Gerard McElvaney; Elizabeth Tullis; Scott C Bell; Pavel Dřevínek; Matthias Griese; Edward F McKone; Claire E Wainwright; Michael W Konstan; Richard Moss; Felix Ratjen; Isabelle Sermet-Gaudelus; Steven M Rowe; Qunming Dong; Sally Rodriguez; Karl Yen; Claudia Ordoñez; J Stuart Elborn
Journal:  N Engl J Med       Date:  2011-11-03       Impact factor: 91.245

Review 5.  Cystic fibrosis.

Authors:  Brian P O'Sullivan; Steven D Freedman
Journal:  Lancet       Date:  2009-05-04       Impact factor: 79.321

6.  Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770.

Authors:  Fredrick Van Goor; Sabine Hadida; Peter D J Grootenhuis; Bill Burton; Dong Cao; Tim Neuberger; Amanda Turnbull; Ashvani Singh; John Joubran; Anna Hazlewood; Jinglan Zhou; Jason McCartney; Vijayalaksmi Arumugam; Caroline Decker; Jennifer Yang; Chris Young; Eric R Olson; Jeffery J Wine; Raymond A Frizzell; Melissa Ashlock; Paul Negulescu
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-21       Impact factor: 11.205
  6 in total
  26 in total

Review 1.  In Vitro Models to Study Human Lung Development, Disease and Homeostasis.

Authors:  Alyssa J Miller; Jason R Spence
Journal:  Physiology (Bethesda)       Date:  2017-05

2.  Canadian pharmacare: looking back, looking forward.

Authors:  Steven G Morgan; Jamie R Daw
Journal:  Healthc Policy       Date:  2012-08

3.  Benzopyrimido-pyrrolo-oxazine-dione (R)-BPO-27 Inhibits CFTR Chloride Channel Gating by Competition with ATP.

Authors:  Yonjung Kim; Marc O Anderson; Jinhong Park; Min Goo Lee; Wan Namkung; A S Verkman
Journal:  Mol Pharmacol       Date:  2015-07-14       Impact factor: 4.436

Review 4.  Pharmacogenomic information in drug labels: European Medicines Agency perspective.

Authors:  F Ehmann; L Caneva; K Prasad; M Paulmichl; M Maliepaard; A Llerena; M Ingelman-Sundberg; M Papaluca-Amati
Journal:  Pharmacogenomics J       Date:  2015-02-24       Impact factor: 3.550

5.  Future translational applications from the contemporary genomics era: a scientific statement from the American Heart Association.

Authors:  Caroline S Fox; Jennifer L Hall; Donna K Arnett; Euan A Ashley; Christian Delles; Mary B Engler; Mason W Freeman; Julie A Johnson; David E Lanfear; Stephen B Liggett; Aldons J Lusis; Joseph Loscalzo; Calum A MacRae; Kiran Musunuru; L Kristin Newby; Christopher J O'Donnell; Stephen S Rich; Andre Terzic
Journal:  Circulation       Date:  2015-04-16       Impact factor: 29.690

Review 6.  Cerebral artery myogenic reactivity: The next frontier in developing effective interventions for subarachnoid hemorrhage.

Authors:  Darcy Lidington; Jeffrey T Kroetsch; Steffen-Sebastian Bolz
Journal:  J Cereb Blood Flow Metab       Date:  2017-11-14       Impact factor: 6.200

7.  Targeted rescue of a polycystic kidney disease mutation by lysosomal inhibition.

Authors:  Alexis Hofherr; Claudius J Wagner; Terry Watnick; Michael Köttgen
Journal:  Kidney Int       Date:  2016-01-06       Impact factor: 10.612

8.  The discovery of medicines for rare diseases.

Authors:  David C Swinney; Shuangluo Xia
Journal:  Future Med Chem       Date:  2014-06       Impact factor: 3.808

9.  Playing well with others! Initiating and sustaining successful collaborations between industry, academia and government.

Authors:  Craig J Thomas; John C McKew
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

10.  Progress in cystic fibrosis and the CF Therapeutics Development Network.

Authors:  Steven M Rowe; Drucy S Borowitz; Jane L Burns; John P Clancy; Scott H Donaldson; George Retsch-Bogart; Scott D Sagel; Bonnie W Ramsey
Journal:  Thorax       Date:  2012-10       Impact factor: 9.139
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.